CA2476446A1 - Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases - Google Patents
Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases Download PDFInfo
- Publication number
- CA2476446A1 CA2476446A1 CA002476446A CA2476446A CA2476446A1 CA 2476446 A1 CA2476446 A1 CA 2476446A1 CA 002476446 A CA002476446 A CA 002476446A CA 2476446 A CA2476446 A CA 2476446A CA 2476446 A1 CA2476446 A1 CA 2476446A1
- Authority
- CA
- Canada
- Prior art keywords
- vwf
- inhibitors
- treatment
- sodium
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 19
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 11
- 239000011734 sodium Substances 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 10
- 239000001257 hydrogen Substances 0.000 title claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 title abstract description 4
- 230000001732 thrombotic effect Effects 0.000 title abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 67
- 102100036537 von Willebrand factor Human genes 0.000 claims abstract description 67
- 229960001134 von willebrand factor Drugs 0.000 claims abstract description 67
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 25
- 108010035766 P-Selectin Proteins 0.000 claims description 15
- 230000001154 acute effect Effects 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 230000010410 reperfusion Effects 0.000 claims description 14
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 claims description 12
- 229950008393 cariporide Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 208000030090 Acute Disease Diseases 0.000 claims description 7
- 208000017667 Chronic Disease Diseases 0.000 claims description 7
- 229920000669 heparin Polymers 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- -1 certroparin Chemical compound 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 230000002917 arthritic effect Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 229960004969 dalteparin Drugs 0.000 claims description 2
- 229960000610 enoxaparin Drugs 0.000 claims description 2
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 229960004762 parnaparin Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- 229960005062 tinzaparin Drugs 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 102000008212 P-Selectin Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 abstract description 20
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 102100023472 P-selectin Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 208000010444 Acidosis Diseases 0.000 description 9
- 102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 9
- 230000007950 acidosis Effects 0.000 description 8
- 208000026545 acidosis disease Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004269 weibel-palade body Anatomy 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 230000000758 acidotic effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007951 extracellular acidosis Effects 0.000 description 5
- 210000005003 heart tissue Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010054218 Factor VIII Proteins 0.000 description 4
- 102000001690 Factor VIII Human genes 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 229960000301 factor viii Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000012105 intracellular pH reduction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108091006647 SLC9A1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical class NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001292 preischemic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 150000003714 vitamin K1 derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Inhibitors of cellular sodium/hydrogen exchangers display an inhibiting effect on the secretion of von-Willebrand factor and/or increased expression of P-selektin. Said inhibitors can thus be used for the treatment of thrombotic and inflammatory diseases.
Description
Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders The invention relates to the use of inhibitors of the cellular sodium/hydrogen exchanger in human and veterinary medicine for the prevention and treatment of acute or chronic diseases caused by elevated levels of von Willebrand factor in the blood. The inhibitors can therefore be employed for the treatment of thrombotic and inflammatory disorders.
Inhibitors of the sodium/hydrogen exhanger (NHE) have in recent years been characterized in numerous preclinical studies as substances which are suitable in a superior manner in cases of cardiac hypopertusion for protecting the cardiac tissue which is endangered by the acute onset of the ischemic event from death. Protection of cardiac tissue by NHE inhibitors encompasses all degrees of harm caused by the hypoperfusion, starting from cardiac arrhythmias via hypercontraction of the myocardium and temporary loss of function up to death of cardiac tissue and the permanent damage associated therewith.
The mechanism of action of NHE inhibitors which is important in the acute ischemic event comprises their reduction of the enhanced influx of sodium ions which arises in acutely hypoperfused tissue due to activation of the NHE as a consequence of intracellular acidification. This delays the situation of tissue sodium overload. Since there is coupling of sodium and calcium ion transport in cardiac tissue, this prevents the life-threatening calcium overload of heart cells.
It is also known that NHE inhibitors provide protection to the central nervous system (CNS), such agents protecting the CNS, in a similar way to the heart, against acute ischemic states. These states are caused by acute hypoperfusion and thus by a deficient supply of nutrients, oxygen or minerals. Such ischemic harm to the CNS is particularly pronounced in cases of central infarctions such as stroke. Thus, as expected, no protective effects of NHE inhibitors against these acute events were observable where blood flow was normal and healthy, because there was no acute onset of ischemic harm to cardiac tissue or CNS
tissue.
Inhibitors of the sodium/hydrogen exhanger (NHE) have in recent years been characterized in numerous preclinical studies as substances which are suitable in a superior manner in cases of cardiac hypopertusion for protecting the cardiac tissue which is endangered by the acute onset of the ischemic event from death. Protection of cardiac tissue by NHE inhibitors encompasses all degrees of harm caused by the hypoperfusion, starting from cardiac arrhythmias via hypercontraction of the myocardium and temporary loss of function up to death of cardiac tissue and the permanent damage associated therewith.
The mechanism of action of NHE inhibitors which is important in the acute ischemic event comprises their reduction of the enhanced influx of sodium ions which arises in acutely hypoperfused tissue due to activation of the NHE as a consequence of intracellular acidification. This delays the situation of tissue sodium overload. Since there is coupling of sodium and calcium ion transport in cardiac tissue, this prevents the life-threatening calcium overload of heart cells.
It is also known that NHE inhibitors provide protection to the central nervous system (CNS), such agents protecting the CNS, in a similar way to the heart, against acute ischemic states. These states are caused by acute hypoperfusion and thus by a deficient supply of nutrients, oxygen or minerals. Such ischemic harm to the CNS is particularly pronounced in cases of central infarctions such as stroke. Thus, as expected, no protective effects of NHE inhibitors against these acute events were observable where blood flow was normal and healthy, because there was no acute onset of ischemic harm to cardiac tissue or CNS
tissue.
Numerous classes of substances which intervene in the interplay of coagulation factors and thus cause cessation of the coagulation cascade are described in the prior art. Likewise, numerous action principles which do not suppress thrombus formation, but cause the dissolution (lysis) of thrombi which have already formed, have been developed. Some of these action principles, which intervene at a wide variety of junction points in said cascade, have been introduced into therapy to prevent thrombogenesis, such as derivatives of the vitamin K group (phylloquinones), factor VIII and factor IX products, platelet aggregation inhibitors such as acetylsalicylic acid, dipyridamole and ticlopidine, anticoagulants such as heparins or heparinoids.
The blood coagulation cascade can be divided mechanistically into two pathways as depicted in the following diagram, namely into an intrinsic and an extrinsic route, the two of which finally meet in the activation of factor X
and the resulting generation of thrombin and subsequently of fibrin:
Intrinsic Extrinsic XII --~ Xlla VII + TF
xl ~ xla Ix ---~ Ixa X --~ Xa Platelet Aggregation Prothrombin ---~ Thrombin Fibrinogen ----~ Fibrin Scheme 1: blood coagulation cascade It is important in the therapeutic use of such blood coagulation inhibitors that the inhibition of coagulation achieved is not too strong or complete, which would inhibit the formation of microthrombi and microcoagulations which are vital and which must take place at the microtraumata which are continually happening.
Only imprecise adjustment of the degree of inhibition of coagulation is possible as a result of differences in the response of the particular individual at a particular time, and the degree must be carefully monitored where possible. If these many small coagulation processes which ure Nermanently taking place are inhibited there is a high risk of extensive hemorrhage (hemophilia).
The disadvantage of the known therapeutic agents available on the market which intervene as inhibitors in the coagulation event is therefore the high risk of bleeding complications. The risk of life-threatening hemorrhage exists especially during high-dose thrombolysis therapy, e.g. during therapy of acute myocardial infarction or pulmonary embolism. There is thus an urgent need for therapeutic agents which do not entail a risk of increased tendency to bleeding despite overdosage.
Many of the known anticoagulant substances act by exerting an effect on the blood platelets, the thrombocytes, and inhibiting their function or inhibiting their activation. The endothelium also evidently plays a central part in the coagulation event. Thus, for example, the von Willebrand factor (vWF) which is necessary for coagulation is produced for the most part in endothelial cells and is secreted by them permanently (constitutively) into the circulating blood in order to ensure the necessary coagulation processes in the blood. A
considerable part of the produced vWF is stored in cytoplasmic granules, called Weibel-Palade bodies, and released as required through stimulation of endothelial cells. If endothelial cells are unable to produce vWF and deliver it to the blood, the result is the well known genetic vWF-dependent disease, von Willebrand-Jurgens syndrome, which is characterized by hemorrhages which can scarcely be stopped.
It is only in recent years that disorders caused by elevated concentrations of vWF
in the blood, thus inducing, for example, an increased tendency to blood coagulation and inflammatory processes, have become known. Thus, Kamphuisen et al, demonstrate on the basis of a large number of studies in their publication "Elevated factor VIII levels and the risk of thrombosis"
(Arterioscler.
Thromb. Vasc. Biol. 21 (5):731-738 (2001 )) that there is a significant association between elevated vWF levels in the blood and an increased rate of thrombotic disorders. Factor VIII forms with vWF a complex as necessary precondition for blood coagulation. It has been possible to establish that high levels of von Willebrand factor and (vWF) and of vWF-bound factor VIII in the blood represent a clear thrombosis risk factor. However, antithrombotic agents which antagonize the stabilizing binding of vWF to fac~or VIII may also be disadvantageous because, in the event of overdosage, substantial inhibition of blood coagulation and dangerous tendencies to bleeding must be expected.
In the attempt to find effective compounds for the treatment of acute or chronic diseases caused by elevated levels of von Willebrand factor in the blood, it has now been found that the compounds employed according to the invention inhibit the release of von Willebrand factor from endothelial cells. The compounds of the invention inhibit the massive pH-dependent release of vWF
which accumulates during ischemia.
Whereas the secretion takes place normally and constitutively at the normal pH
of blood which is known to be about 7.4, and part of the vWF is stored in Weibel-Palade bodies, it has now been found that there is a delay and reduction in the release of vWF as the pH falls. Exocytosis of the Weibel-Palade bodies in which the vWF is packaged is increasingly inhibited as the pH declines. Thus, under acidotic conditions, there is a significant increase in Weibel-Palade bodies and thus extensive accumulation of vWF in the endothelial cell, and a reduced constitutive and stimulated vWF secretion. This can be visualized by staining procedures and demonstrated by quantitative measurements of vWF in the supernatant. Such acidotic states with significant pH reductions below 7 occur, for example, in cases of tissue ischemia. At the instant of realkalinization and endothelial cell stimulation, which corresponds to the reperfusion state, within seconds exocytosis takes place, and thus emptying of the Weibel-Palade bodies (WPB), thus leading to massive release of the prothrombotic risk factor.
Besides vWF, the Weibel-Palade bodies also store the transmembrane protein P-selectin (Wagner, D.D. 1993, Thromb. Haemost., 70:105-110).
P-Selectin is located in the vesicle membrane and, after vesicle fusion (exocytosis), is incorporated into the plasma membrane of the endothelial cell.
This means that every Weibel-Palade body exocytosis leads not only to increased vWF release but also to increased P-selectin expression in the endothelial cell membrane. The examples show vWF secretion (quantitive measurement by ELISA) during acidosis and during subsequent repertusion. In 5 parallel, these quantitative measurements are confirmed by immunofluorescence data G~1 the',~'eibci-Palade bodies. The measured vWF is thus not only a marker of increased (increase in vWF secretion) or reduced (decrease in vWF secretion) tendency to thrombosis (via increase in platelet aggregation), but also a direct marker of increased or reduced P-selectin expression in the endothelial cell membrane. P-Selectin serves as anchor for leukocytes and thus the initial inflammatory reaction (Vestweber, D., Blanks, J.E.
1999, Physiol. Rev., 79:181-213; Issekutz, A.C., Issekutz, T.B. 2002, J.
Immunol., 168:1934-1939). The pathophysiological significance is wide-ranging and confirmed for ischemia/reperfusion disorders, thromboses and arteriosclerosis (Massberg, S., et al., 1998, Blood, 92:507-515;
Kita, T., et al., 2001, Ann. N. Y. Acad. Sci., 947:199-205). Besides the significance of P-selectin as marker of inflammation and initiator of inflammation, it plays an essential part in the process of cancer dissemination (Varki, A., Varki, N.M.
2001, Braz. J. Med. Biol. Res. 34:711-717) and during various inflammations of joints (arthritis) (Veihelmann, A. et al, 1999, Microcirculation, 6: 281-290;
Mclnnes, I.B., et al., 2001, J. Immunol., 167:4075-4082). Thus the mode of action of the substances described here may also find use as therapeutic agent for all the abovementioned P-selectin-associated disorders.
The invention therefore relates to the use of inhibitors of the sodium/hydrogen exchanger for producing medicaments for the prophylaxis and therapy of acute and chronic diseases caused by elevated levels of von Willebrand factor in blood.
The invention further relates to the use of at least one of the following compounds N\ 'NH2 H3C '~-N~NHZ
O; S
O
N
N\ N H 2 ,SO v O O H
O
O N
~N
N\ NH2 O:S
O NH
\/o N\ 'NH2 'l~
O NHZ
O N~NH2 w NH2 ~O ~N
~O
N
N~ NHZ
O
~N~N
H ~ I
N
NH
~ NH
O N =/
O
N
N O
N
N~ O
or F
N~N~~N H2 and/or all stereoisomeric forms of the abovementioned compounds and/or mixtures of these forms in any ratio, and/or of the physiologically tolerated salts of the abovementioned compounds for producing a medicament for the prophylaxis and therapy of acute or chronic diseases caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
The invention further relates to the use of cariporide H C- N~N Hz 'l3 for producing a medicament for the prophylaxis and therapy of acute or chronic diseases which are caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
The abovementioned compounds are known and can be prepared as described, for example, in EP 0 416 499, EP 0 556 673, EP 0 589 336, EP 0 b22 356, EP 0 b99 66b, EP 0 708 088, EP 0 719 766, EP 0 726 254, EP 0 787 728, EP 0 972 767, DE 19529612, DE 19601303, WO 99 00379 or T.Kawamoto et al., Potent and selective Inhibition of the hur roan Na+i I-1+ exchanger isoform NHE1 by a novel aminoguanidine derivative T-162559, Eur.J. Pharmacol. 420 (2001), 1-8.
Where the abovementioned compounds allow diastereoisomeric or enantiomeric forms and result as mixtures thereof in the chosen synthesis, separation into the pure stereoisomers takes place either by chromatography on an optionally chiral support material or, if the racemic abovementioned compounds are able to form salts, by fractional crystallization of the diastereomeric salts formed with an optically active base or acid as aid.
Examples of suitable chiral stationary phases for separation of enantiomers by thin-layer or column chromatography are modified silica gel supports (so-called Pirkle phases) and high molecular weight carbohydrates such as triacetylcellulose. Gas chromatographic methods on chiral stationary phases can also be used for analytical purposes after appropriate derivatization known to the skilled worker. To separate enantiomers of the racemic carboxylic acids, diastereomeric salts differing in solubility are formed using an optically active, usually commercially available, base such as (-)-nicotine, (+)- and (-)-phenylethylamine,quinine bases, L-lysine or L- and D-arginine, the less soluble component is isolated as solid, the more soluble diastereomer is deposited from the mother liquor, and the pure enantiomers are obtained from the diastereomeric salts obtained in this way. It is possible in the same way in principle to convert the racemic compounds of the formula I containing a basic group such as an amino group with optically active acids such as (+)-camphor-10-sulfonic acid, D- and L-tartaric acid, D- and L- lactic acid and (+) and (-)-mandelic acid into the pure enantiomers. Chiral compounds containing alcohol or amine functions can also be converted with appropriately activated or, where appropriate, N-protected enantiopure amino acids into the corresponding esters or amides, or conversely convert chiral carboxylic acids with carboxyl-protected enantiopure amino acids into the amides or with enantiopure hydroxy carboxylic acids such as lactic acid into the corresponding chiral esters. The chirality of the amino acid or alcohol residue produced in enantiopure form can then be utilized for separating the isomers by carrying out a separation of the diastereomers which are now present by crystallization or chromatography on suitable stationary phases and then eliminating the 5 included chiral moiety by suitable methods.
Acidic or basic products of the abovementioned compounds can exist in the form of their salts or in free form. Preference is given to pharmacologically suitable salts, e.g. alkali metal or alkaline earth metal salts, or hydrochlorides, 10 hydrobromides, sulfates, hemisulfates, all possible phosphates, and salts of amino acids, natural bases or carboxylic acids.
Physiologically tolerated salts are prepared from the abovementioned compounds able to form salts, including the stereoisomeric forms thereof, in a manner known per se. The carboxylic acids and hydroxamic acids form with basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or else basic amino acids, for example lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or optionally substituted ammonium salts. Where the abovementioned compounds have basic groups, stable acid addition salts can also be prepared with strong acids.
Suitable for this purpose are both inorganic and organic acids, such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, benzenesulfonic, p-toluenesulfonic, 4-bromobenzenesulfonic, cyclohexylsulfamic, trifluoromethylsulfonic, acetic, oxalic, tartaric, succinic or trifluoroacetic acid. Methanesulfonic acid salts of the abovementioned compounds are particularly preferred.
Owing to the pharmacological properties, the abovementioned compounds ace suitable for the prophylaxis and therapy of acute or chronic diseases which are caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
These include thrombotic disorders provoked by ischemic states with subsequent reperfusion; such as thromboses in acute myocardial, mesenteric or else cerebral infarction; thrombotic disorders occurring during or after surgical operations;
pulmonary embolisms; deep vein thromboses as occur at an increased rate after prolonged restriction of blood flow, especially in the lower extremities, for example after prolonged lying or sitting, and imflammatory disorders as occur during ischemia and subsequent reperfusion, during vasculitis (e.g. associated with autoimmune disease or connective tissue disease).
These also include disorders which are caused by increased expression of P-selectin, such as incipient inflammatory reactions; but also prophylaxis and treatment of arteriosclerosis; and prophylaxis and treatment of cancer; also inflammation of joints and arthritic disorders such as rheumatoid arthritis.
Administration of the medicaments of the invention can take place by oral, inhalational, rectal or transdermal administration or by subcutaneous, intraarticular, intraperitoneal or intravenous injection. Oral administration is preferred.
The invention also relates to a process for producing a medicament, which comprises converting at least one of the abovementioned compounds with a pharmaceutically suitable and physiologically tolerated carrier and, where appropriate, ofiher suitable active ingredients, additives or excipients into a suitable dosage form.
The abovementioned compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily suspensions or aqueous or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can moreover take place both as dry and as wet granules. Examples of suitable oily carriers or solvents are vegetable or animal oils, such as sunflower oil or fish liver oil.
For subcutaneous, intraperitoneal or intravenous administration, the active compounds are converted into solution, suspension or emulsion if desired with the substances suitable for this purpose, such as solubilizers, emulsifiers or other excipients. Examples of suitable solvents are physiological saline or alcohols, e.g.
ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
Also used are conventional aids such as carriers, disintegrants, binders, coating agents, swelling agents, glidants or lubricants; flavcrings, sweeteners and solubilizers. Excipients which are frequently used and which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and derivatives thereof, animal and vegetable oils such as fish liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and monohydric and polyhydric alcohols such as glycerol.
The abovementioned compounds are preferably produced and administered as pharmaceutical products in dosage units, where one unit contains as active ingredient a defined dose of the compound of the formula I. They can for this purpose be administered orally in doses of from 0.01 mg/kg/day to 25.0 mg/kg/day, preferably 0.01 mg/kg/day to 5.0 mg/kg/day or parenterally in doses of from 0.001 mg/kg/day to 5 mg/kg/day, preferably 0.001 mg/kg/day to 2.5 mg/kg/day. The dosage may also be increased in severe cases. However, lower doses also suffice in many cases. These data relate to an adult weighing about 75 kg.
The abovementioned compounds can be employed alone or in combination with anticoagulant, platelet aggregation-inhibiting or fibrinolytic agents.
Coadministration can take place, for example, with factor Xa inhibitors, standard heparin, low molecular weight heparins such as enoxaparin, dalteparin, certroparin, parnaparin or tinzaparin, direct thrombin inhibitors such as hirudin, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator (tPA).
It is known that the inhibitors of the sodium/hydrogen exchanger affect platelet aggregation and have an adhesion-inhibiting effect (see Rosskopf, Dieter, J.
Thromb. Thrombolysis (1999), 8(1), 15-23; or Nieuwland, Rienk; Akkerman, Jan-Willem Nicolaas. Adv. Mol. Cell Biol. (1997), 18(Platelet), 353-366.
In contrast to the previously described effects on the aggregation of blood platelets, the abovementioned compounds also show inhibition of excessive release of von Willebrand factor. This novel antithrombotic action principle differs from the previously disclosed antithrombotic action principles in a crucial and advantageous manner in that a) it acts only in ischemic tissue in the subsequent repertusion phase, whereas other cells not affected by the ischemia (preischemic) remain completely unaffected, and b) there is no need to worry about any of the dangerous hemorrhagic complications during the lysis therapy.
The invention is explained in more detail by means of examples below.
The following examples demonstrated the effects of an extracellular acidosis (pHex = 6.4) and the effects of the abovementioned compounds of the invention on the intracellular pH (pH~ and the release of von-Willebrand factor (vWF).
All the examples were carried out with human umbilical vein endothelial cells (HUVEC). These comprise primary cell cultures isolated from the umbilical vein.
For the following examples, the cells were cultivated either on gelatinized glass plates (measurement of the intracellular proton concentration) or on cell culture plates (12-well culture plates, Falcon, New Jersey, USA; measurement of vWF
release) after the first passage.
Example l:
Measurement of the intracellular pH
To measure the intracellular proton concentration (pHa, the HUVECs were loaded with the pH-sensitive fluorescent dye BCECF-AM (2',7'-bis(carboxyefihyl)-5(6)-carboxyfluorescein). A Deltascan spectrofluorometer (PTI, Hamburg) was employed for the subsequent fluorescence measurement. This measuring system consists essentially of a UV light source, a monochromator, a photon detector and the Felix and Oscar software packages (PTI, Hamburg) for controlling the system via a computer. After alternate excitation with the wavelengths 439.5 nm (pH-independent) and 490 nm (pH-sensitive), the ratio of the measured emissions of the BCECF (ratio) was reported and the pH was found after a calibration.
The measuring cell is designed so that the parameters of temperature and carbon dioxide partial pressure in the system are controlled during continuous perfusion.
For the repertusion simulation, the experimental conditions were set at 37°C and a carbon dioxide partial pressure of 5~ or 10~ by gassing the system and perfusate.
In the experiment there was initially preincubation with sodium bicarbonate buffer pHex 6.4 for 60 minutes in order to simulate respiratory metabolic acidosis.
The initiation pertusion was then changed to sodium bicarbonate buffer of pH 7.4 with lO,uM histamine as repertusion simulation.
These control experiments were compared with an experiment in which the NHE
inhibitor cariporide was added in a concentration of lO,uM to the reperfusion buffer.
The results of several experiments have been summarized in Tables 1 and 2.
Table 1: Intracellular pH during extracellular acidosis (pH, (acidosis)) of at least 15 minutes and under control conditions (Co).
Table 1:
pH; (Acidosis) 6.53 0.02 (mean SEM) pH; (Co) 7.23 0.02 (mean SEM) amn m n m mt_.n iVUW .7 t.ICVIUIIVI I IIUI11 Ifle llleQfl Extracellular acidosis leads to intracellular acidification which persists during the acidosis. The intracellular acidotic pH is virtually identical to the extracellular pH
(applied extracellular acidosis pHex = 6.4).
Table 2: Repertusion with experimental buffer containing cariporide (HOE) and control buffer (Co). The initial rates of increase in the pH, values was found after 60 minutes of acidosis from the measurements during the first 30 seconds after reperfusion.
Table 2:
Rate of pH increase (0 pH / min) Individual experiments Mean SEM
0.97 1.04 Co 0.89 0.97 0.04 0.88 1.07 0.30 0.24 HOE 0.23 0.27 0.02 0.34 0.24 When the extracellular pH changed from 6.4 to 7.4 there was a reduction by a factor of 3.6 in the rate of increase in intracellular pH compared with the control.
Thus, it is possible by using cariporide during reperfusion to reduce significantly the rate of realkalinization.
Example 2 Measurement of vWF release after repertusion The measurements were carried out in a Heraeus Heracell incubator. This made it possible to calculate the umbilical vein endothelial cells under controlled physiological conditions (temperature 37°C, relative humidity 100, pC02 constant at 5~) and to ensure rapid change of different cell culture media.
Said cells were initially incubated with acidotic medium (pH 6.4 composed of the ingredients: medium M199 w/Earle's & amino acids, w/L-glutamine, w/o NaHC03, w/o Hepes + 0.0848 NaHC03 / I) or pH standard medium (pH 7.4 composed of the ingredients: medium M199 w/Earle's & amino acids, w/L-glutamine, w/o NaHCO~, w/o Hepes + 2.2008 NaHC03 / I) for one, three or 48 hours. Before starting the reperfusion, samples of supernatant were taken to determine the vWF concentration under acidotic conditions (vWFa°~d~,~
and control conditions (vWF~~. To simulate reperfusion, the medium was changed to one with a pH of 7.4 (ingredients: medium M 199 w/Earle's & amino acids, w/L-glutamine, w/o NaHC03, w/o Hepes + 2.200 g NaHC03 / I + lO,uM histamine) to which the NHE inhibitor cariporide was added in a concentration of lO,uM.
Change to the same medium without corresponding addition of inhibitor served as control.
The samples taken from the supernatant were used to determine the vWF
concentration. This was done by an ELISA method (enzyme-linked immuno sorbent assay) using specific antibodies. The vWF content of standard human plasma (Behring, Marburg) is calculated using an international standard (2'~
International Standard 87/718; National Institute for Biological Standards and Control, London).
Table 3: vWF conzentration in the cell supernatant under acidotic (vWF~,~,~
and under control conditions (vWF~~, measured after incubation for 15 minutes. The vWF concentration under control conditions is set at 100.
Table 3.
vW F~o 100~~
vWFa~d~,s (constitutive) 46 1.1 VWFa~,ao~s (stimulated, histamine52 2.5~
NM) The acidosis led to a distinct decrease in vWF secretion, both the constitutive secretion and the stimulated Weibei-Palade body secretion. The vWF secretion was reduced by a factor of 2 compared with control cells during acidosis (pHex = 6.4).
Table 4: vWF secretion was measured during a 10-minute repertusion time with stimulation. The vWF secretion of the control cells (vWF~~ was set at 100. The vWF concentration during the repertusion of preacidotic cells (vWF~,~ and the vWF concentration durlrig reperfusion of preacidotic cells in the presence of 1 O,uM of cariporide (vWF,,~) have been indicated as values relative to the control values. Control cells were incubated with cariporide (vWF~o+,~) Table 4:
vWF~o 100 vWF~o+HOe 106 t 3.06 vWFa~,d~,s 193 t 8.0~
vWF,~ 139 16~
During the reperfusion there was a large increase in vWF secretion by a factor of 2. Blockade of the NHE with cariporide reduces the increased vWF secretion by almost 60~ and thus approaches the control values. Control cells incubated with cariporide (10 ~.M) showed no increase or decrease in vWF secretion.
The examples showed that extracellular acidosis as present for example during ischemia led to an intracellular acidosis, resulting in reduced (constitutive and stimulated) vWF secretion and a reduced P-selectin expression. The subsequent reperfusion and stimulation of the endothelial cells brought about rapid intracellular realkalinization. There was a simultaneous great enhancement of the increased vWF secretion and increased P-selectin expression. A delay of the realkalinization with cariporide reduced the increased vWF secretion and P-selectin expression and thus the possible thrombosis and inflammatory reactions. The examples showed that the intracellular pH is determined by the extracellular pH. Secretion by the endothelial cells is in turn determined by the intracellular pH. It is thus possible, by inhibiting realkalinization, to reduce greatly the known endothelial cell activation during the reperfusion phase and the worry, connected therewith, about rethrombosis (vWF secretion) and inflammation. Incubation of healthy, non-acidotic control cells with cariporide showed no effect. This indicates a low potential for side effects and prevents an excessive tendency to bleeding. The agent acts only where ischemia is present.
The blood coagulation cascade can be divided mechanistically into two pathways as depicted in the following diagram, namely into an intrinsic and an extrinsic route, the two of which finally meet in the activation of factor X
and the resulting generation of thrombin and subsequently of fibrin:
Intrinsic Extrinsic XII --~ Xlla VII + TF
xl ~ xla Ix ---~ Ixa X --~ Xa Platelet Aggregation Prothrombin ---~ Thrombin Fibrinogen ----~ Fibrin Scheme 1: blood coagulation cascade It is important in the therapeutic use of such blood coagulation inhibitors that the inhibition of coagulation achieved is not too strong or complete, which would inhibit the formation of microthrombi and microcoagulations which are vital and which must take place at the microtraumata which are continually happening.
Only imprecise adjustment of the degree of inhibition of coagulation is possible as a result of differences in the response of the particular individual at a particular time, and the degree must be carefully monitored where possible. If these many small coagulation processes which ure Nermanently taking place are inhibited there is a high risk of extensive hemorrhage (hemophilia).
The disadvantage of the known therapeutic agents available on the market which intervene as inhibitors in the coagulation event is therefore the high risk of bleeding complications. The risk of life-threatening hemorrhage exists especially during high-dose thrombolysis therapy, e.g. during therapy of acute myocardial infarction or pulmonary embolism. There is thus an urgent need for therapeutic agents which do not entail a risk of increased tendency to bleeding despite overdosage.
Many of the known anticoagulant substances act by exerting an effect on the blood platelets, the thrombocytes, and inhibiting their function or inhibiting their activation. The endothelium also evidently plays a central part in the coagulation event. Thus, for example, the von Willebrand factor (vWF) which is necessary for coagulation is produced for the most part in endothelial cells and is secreted by them permanently (constitutively) into the circulating blood in order to ensure the necessary coagulation processes in the blood. A
considerable part of the produced vWF is stored in cytoplasmic granules, called Weibel-Palade bodies, and released as required through stimulation of endothelial cells. If endothelial cells are unable to produce vWF and deliver it to the blood, the result is the well known genetic vWF-dependent disease, von Willebrand-Jurgens syndrome, which is characterized by hemorrhages which can scarcely be stopped.
It is only in recent years that disorders caused by elevated concentrations of vWF
in the blood, thus inducing, for example, an increased tendency to blood coagulation and inflammatory processes, have become known. Thus, Kamphuisen et al, demonstrate on the basis of a large number of studies in their publication "Elevated factor VIII levels and the risk of thrombosis"
(Arterioscler.
Thromb. Vasc. Biol. 21 (5):731-738 (2001 )) that there is a significant association between elevated vWF levels in the blood and an increased rate of thrombotic disorders. Factor VIII forms with vWF a complex as necessary precondition for blood coagulation. It has been possible to establish that high levels of von Willebrand factor and (vWF) and of vWF-bound factor VIII in the blood represent a clear thrombosis risk factor. However, antithrombotic agents which antagonize the stabilizing binding of vWF to fac~or VIII may also be disadvantageous because, in the event of overdosage, substantial inhibition of blood coagulation and dangerous tendencies to bleeding must be expected.
In the attempt to find effective compounds for the treatment of acute or chronic diseases caused by elevated levels of von Willebrand factor in the blood, it has now been found that the compounds employed according to the invention inhibit the release of von Willebrand factor from endothelial cells. The compounds of the invention inhibit the massive pH-dependent release of vWF
which accumulates during ischemia.
Whereas the secretion takes place normally and constitutively at the normal pH
of blood which is known to be about 7.4, and part of the vWF is stored in Weibel-Palade bodies, it has now been found that there is a delay and reduction in the release of vWF as the pH falls. Exocytosis of the Weibel-Palade bodies in which the vWF is packaged is increasingly inhibited as the pH declines. Thus, under acidotic conditions, there is a significant increase in Weibel-Palade bodies and thus extensive accumulation of vWF in the endothelial cell, and a reduced constitutive and stimulated vWF secretion. This can be visualized by staining procedures and demonstrated by quantitative measurements of vWF in the supernatant. Such acidotic states with significant pH reductions below 7 occur, for example, in cases of tissue ischemia. At the instant of realkalinization and endothelial cell stimulation, which corresponds to the reperfusion state, within seconds exocytosis takes place, and thus emptying of the Weibel-Palade bodies (WPB), thus leading to massive release of the prothrombotic risk factor.
Besides vWF, the Weibel-Palade bodies also store the transmembrane protein P-selectin (Wagner, D.D. 1993, Thromb. Haemost., 70:105-110).
P-Selectin is located in the vesicle membrane and, after vesicle fusion (exocytosis), is incorporated into the plasma membrane of the endothelial cell.
This means that every Weibel-Palade body exocytosis leads not only to increased vWF release but also to increased P-selectin expression in the endothelial cell membrane. The examples show vWF secretion (quantitive measurement by ELISA) during acidosis and during subsequent repertusion. In 5 parallel, these quantitative measurements are confirmed by immunofluorescence data G~1 the',~'eibci-Palade bodies. The measured vWF is thus not only a marker of increased (increase in vWF secretion) or reduced (decrease in vWF secretion) tendency to thrombosis (via increase in platelet aggregation), but also a direct marker of increased or reduced P-selectin expression in the endothelial cell membrane. P-Selectin serves as anchor for leukocytes and thus the initial inflammatory reaction (Vestweber, D., Blanks, J.E.
1999, Physiol. Rev., 79:181-213; Issekutz, A.C., Issekutz, T.B. 2002, J.
Immunol., 168:1934-1939). The pathophysiological significance is wide-ranging and confirmed for ischemia/reperfusion disorders, thromboses and arteriosclerosis (Massberg, S., et al., 1998, Blood, 92:507-515;
Kita, T., et al., 2001, Ann. N. Y. Acad. Sci., 947:199-205). Besides the significance of P-selectin as marker of inflammation and initiator of inflammation, it plays an essential part in the process of cancer dissemination (Varki, A., Varki, N.M.
2001, Braz. J. Med. Biol. Res. 34:711-717) and during various inflammations of joints (arthritis) (Veihelmann, A. et al, 1999, Microcirculation, 6: 281-290;
Mclnnes, I.B., et al., 2001, J. Immunol., 167:4075-4082). Thus the mode of action of the substances described here may also find use as therapeutic agent for all the abovementioned P-selectin-associated disorders.
The invention therefore relates to the use of inhibitors of the sodium/hydrogen exchanger for producing medicaments for the prophylaxis and therapy of acute and chronic diseases caused by elevated levels of von Willebrand factor in blood.
The invention further relates to the use of at least one of the following compounds N\ 'NH2 H3C '~-N~NHZ
O; S
O
N
N\ N H 2 ,SO v O O H
O
O N
~N
N\ NH2 O:S
O NH
\/o N\ 'NH2 'l~
O NHZ
O N~NH2 w NH2 ~O ~N
~O
N
N~ NHZ
O
~N~N
H ~ I
N
NH
~ NH
O N =/
O
N
N O
N
N~ O
or F
N~N~~N H2 and/or all stereoisomeric forms of the abovementioned compounds and/or mixtures of these forms in any ratio, and/or of the physiologically tolerated salts of the abovementioned compounds for producing a medicament for the prophylaxis and therapy of acute or chronic diseases caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
The invention further relates to the use of cariporide H C- N~N Hz 'l3 for producing a medicament for the prophylaxis and therapy of acute or chronic diseases which are caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
The abovementioned compounds are known and can be prepared as described, for example, in EP 0 416 499, EP 0 556 673, EP 0 589 336, EP 0 b22 356, EP 0 b99 66b, EP 0 708 088, EP 0 719 766, EP 0 726 254, EP 0 787 728, EP 0 972 767, DE 19529612, DE 19601303, WO 99 00379 or T.Kawamoto et al., Potent and selective Inhibition of the hur roan Na+i I-1+ exchanger isoform NHE1 by a novel aminoguanidine derivative T-162559, Eur.J. Pharmacol. 420 (2001), 1-8.
Where the abovementioned compounds allow diastereoisomeric or enantiomeric forms and result as mixtures thereof in the chosen synthesis, separation into the pure stereoisomers takes place either by chromatography on an optionally chiral support material or, if the racemic abovementioned compounds are able to form salts, by fractional crystallization of the diastereomeric salts formed with an optically active base or acid as aid.
Examples of suitable chiral stationary phases for separation of enantiomers by thin-layer or column chromatography are modified silica gel supports (so-called Pirkle phases) and high molecular weight carbohydrates such as triacetylcellulose. Gas chromatographic methods on chiral stationary phases can also be used for analytical purposes after appropriate derivatization known to the skilled worker. To separate enantiomers of the racemic carboxylic acids, diastereomeric salts differing in solubility are formed using an optically active, usually commercially available, base such as (-)-nicotine, (+)- and (-)-phenylethylamine,quinine bases, L-lysine or L- and D-arginine, the less soluble component is isolated as solid, the more soluble diastereomer is deposited from the mother liquor, and the pure enantiomers are obtained from the diastereomeric salts obtained in this way. It is possible in the same way in principle to convert the racemic compounds of the formula I containing a basic group such as an amino group with optically active acids such as (+)-camphor-10-sulfonic acid, D- and L-tartaric acid, D- and L- lactic acid and (+) and (-)-mandelic acid into the pure enantiomers. Chiral compounds containing alcohol or amine functions can also be converted with appropriately activated or, where appropriate, N-protected enantiopure amino acids into the corresponding esters or amides, or conversely convert chiral carboxylic acids with carboxyl-protected enantiopure amino acids into the amides or with enantiopure hydroxy carboxylic acids such as lactic acid into the corresponding chiral esters. The chirality of the amino acid or alcohol residue produced in enantiopure form can then be utilized for separating the isomers by carrying out a separation of the diastereomers which are now present by crystallization or chromatography on suitable stationary phases and then eliminating the 5 included chiral moiety by suitable methods.
Acidic or basic products of the abovementioned compounds can exist in the form of their salts or in free form. Preference is given to pharmacologically suitable salts, e.g. alkali metal or alkaline earth metal salts, or hydrochlorides, 10 hydrobromides, sulfates, hemisulfates, all possible phosphates, and salts of amino acids, natural bases or carboxylic acids.
Physiologically tolerated salts are prepared from the abovementioned compounds able to form salts, including the stereoisomeric forms thereof, in a manner known per se. The carboxylic acids and hydroxamic acids form with basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or else basic amino acids, for example lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or optionally substituted ammonium salts. Where the abovementioned compounds have basic groups, stable acid addition salts can also be prepared with strong acids.
Suitable for this purpose are both inorganic and organic acids, such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, benzenesulfonic, p-toluenesulfonic, 4-bromobenzenesulfonic, cyclohexylsulfamic, trifluoromethylsulfonic, acetic, oxalic, tartaric, succinic or trifluoroacetic acid. Methanesulfonic acid salts of the abovementioned compounds are particularly preferred.
Owing to the pharmacological properties, the abovementioned compounds ace suitable for the prophylaxis and therapy of acute or chronic diseases which are caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin.
These include thrombotic disorders provoked by ischemic states with subsequent reperfusion; such as thromboses in acute myocardial, mesenteric or else cerebral infarction; thrombotic disorders occurring during or after surgical operations;
pulmonary embolisms; deep vein thromboses as occur at an increased rate after prolonged restriction of blood flow, especially in the lower extremities, for example after prolonged lying or sitting, and imflammatory disorders as occur during ischemia and subsequent reperfusion, during vasculitis (e.g. associated with autoimmune disease or connective tissue disease).
These also include disorders which are caused by increased expression of P-selectin, such as incipient inflammatory reactions; but also prophylaxis and treatment of arteriosclerosis; and prophylaxis and treatment of cancer; also inflammation of joints and arthritic disorders such as rheumatoid arthritis.
Administration of the medicaments of the invention can take place by oral, inhalational, rectal or transdermal administration or by subcutaneous, intraarticular, intraperitoneal or intravenous injection. Oral administration is preferred.
The invention also relates to a process for producing a medicament, which comprises converting at least one of the abovementioned compounds with a pharmaceutically suitable and physiologically tolerated carrier and, where appropriate, ofiher suitable active ingredients, additives or excipients into a suitable dosage form.
The abovementioned compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily suspensions or aqueous or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can moreover take place both as dry and as wet granules. Examples of suitable oily carriers or solvents are vegetable or animal oils, such as sunflower oil or fish liver oil.
For subcutaneous, intraperitoneal or intravenous administration, the active compounds are converted into solution, suspension or emulsion if desired with the substances suitable for this purpose, such as solubilizers, emulsifiers or other excipients. Examples of suitable solvents are physiological saline or alcohols, e.g.
ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
Also used are conventional aids such as carriers, disintegrants, binders, coating agents, swelling agents, glidants or lubricants; flavcrings, sweeteners and solubilizers. Excipients which are frequently used and which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and derivatives thereof, animal and vegetable oils such as fish liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and monohydric and polyhydric alcohols such as glycerol.
The abovementioned compounds are preferably produced and administered as pharmaceutical products in dosage units, where one unit contains as active ingredient a defined dose of the compound of the formula I. They can for this purpose be administered orally in doses of from 0.01 mg/kg/day to 25.0 mg/kg/day, preferably 0.01 mg/kg/day to 5.0 mg/kg/day or parenterally in doses of from 0.001 mg/kg/day to 5 mg/kg/day, preferably 0.001 mg/kg/day to 2.5 mg/kg/day. The dosage may also be increased in severe cases. However, lower doses also suffice in many cases. These data relate to an adult weighing about 75 kg.
The abovementioned compounds can be employed alone or in combination with anticoagulant, platelet aggregation-inhibiting or fibrinolytic agents.
Coadministration can take place, for example, with factor Xa inhibitors, standard heparin, low molecular weight heparins such as enoxaparin, dalteparin, certroparin, parnaparin or tinzaparin, direct thrombin inhibitors such as hirudin, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator (tPA).
It is known that the inhibitors of the sodium/hydrogen exchanger affect platelet aggregation and have an adhesion-inhibiting effect (see Rosskopf, Dieter, J.
Thromb. Thrombolysis (1999), 8(1), 15-23; or Nieuwland, Rienk; Akkerman, Jan-Willem Nicolaas. Adv. Mol. Cell Biol. (1997), 18(Platelet), 353-366.
In contrast to the previously described effects on the aggregation of blood platelets, the abovementioned compounds also show inhibition of excessive release of von Willebrand factor. This novel antithrombotic action principle differs from the previously disclosed antithrombotic action principles in a crucial and advantageous manner in that a) it acts only in ischemic tissue in the subsequent repertusion phase, whereas other cells not affected by the ischemia (preischemic) remain completely unaffected, and b) there is no need to worry about any of the dangerous hemorrhagic complications during the lysis therapy.
The invention is explained in more detail by means of examples below.
The following examples demonstrated the effects of an extracellular acidosis (pHex = 6.4) and the effects of the abovementioned compounds of the invention on the intracellular pH (pH~ and the release of von-Willebrand factor (vWF).
All the examples were carried out with human umbilical vein endothelial cells (HUVEC). These comprise primary cell cultures isolated from the umbilical vein.
For the following examples, the cells were cultivated either on gelatinized glass plates (measurement of the intracellular proton concentration) or on cell culture plates (12-well culture plates, Falcon, New Jersey, USA; measurement of vWF
release) after the first passage.
Example l:
Measurement of the intracellular pH
To measure the intracellular proton concentration (pHa, the HUVECs were loaded with the pH-sensitive fluorescent dye BCECF-AM (2',7'-bis(carboxyefihyl)-5(6)-carboxyfluorescein). A Deltascan spectrofluorometer (PTI, Hamburg) was employed for the subsequent fluorescence measurement. This measuring system consists essentially of a UV light source, a monochromator, a photon detector and the Felix and Oscar software packages (PTI, Hamburg) for controlling the system via a computer. After alternate excitation with the wavelengths 439.5 nm (pH-independent) and 490 nm (pH-sensitive), the ratio of the measured emissions of the BCECF (ratio) was reported and the pH was found after a calibration.
The measuring cell is designed so that the parameters of temperature and carbon dioxide partial pressure in the system are controlled during continuous perfusion.
For the repertusion simulation, the experimental conditions were set at 37°C and a carbon dioxide partial pressure of 5~ or 10~ by gassing the system and perfusate.
In the experiment there was initially preincubation with sodium bicarbonate buffer pHex 6.4 for 60 minutes in order to simulate respiratory metabolic acidosis.
The initiation pertusion was then changed to sodium bicarbonate buffer of pH 7.4 with lO,uM histamine as repertusion simulation.
These control experiments were compared with an experiment in which the NHE
inhibitor cariporide was added in a concentration of lO,uM to the reperfusion buffer.
The results of several experiments have been summarized in Tables 1 and 2.
Table 1: Intracellular pH during extracellular acidosis (pH, (acidosis)) of at least 15 minutes and under control conditions (Co).
Table 1:
pH; (Acidosis) 6.53 0.02 (mean SEM) pH; (Co) 7.23 0.02 (mean SEM) amn m n m mt_.n iVUW .7 t.ICVIUIIVI I IIUI11 Ifle llleQfl Extracellular acidosis leads to intracellular acidification which persists during the acidosis. The intracellular acidotic pH is virtually identical to the extracellular pH
(applied extracellular acidosis pHex = 6.4).
Table 2: Repertusion with experimental buffer containing cariporide (HOE) and control buffer (Co). The initial rates of increase in the pH, values was found after 60 minutes of acidosis from the measurements during the first 30 seconds after reperfusion.
Table 2:
Rate of pH increase (0 pH / min) Individual experiments Mean SEM
0.97 1.04 Co 0.89 0.97 0.04 0.88 1.07 0.30 0.24 HOE 0.23 0.27 0.02 0.34 0.24 When the extracellular pH changed from 6.4 to 7.4 there was a reduction by a factor of 3.6 in the rate of increase in intracellular pH compared with the control.
Thus, it is possible by using cariporide during reperfusion to reduce significantly the rate of realkalinization.
Example 2 Measurement of vWF release after repertusion The measurements were carried out in a Heraeus Heracell incubator. This made it possible to calculate the umbilical vein endothelial cells under controlled physiological conditions (temperature 37°C, relative humidity 100, pC02 constant at 5~) and to ensure rapid change of different cell culture media.
Said cells were initially incubated with acidotic medium (pH 6.4 composed of the ingredients: medium M199 w/Earle's & amino acids, w/L-glutamine, w/o NaHC03, w/o Hepes + 0.0848 NaHC03 / I) or pH standard medium (pH 7.4 composed of the ingredients: medium M199 w/Earle's & amino acids, w/L-glutamine, w/o NaHCO~, w/o Hepes + 2.2008 NaHC03 / I) for one, three or 48 hours. Before starting the reperfusion, samples of supernatant were taken to determine the vWF concentration under acidotic conditions (vWFa°~d~,~
and control conditions (vWF~~. To simulate reperfusion, the medium was changed to one with a pH of 7.4 (ingredients: medium M 199 w/Earle's & amino acids, w/L-glutamine, w/o NaHC03, w/o Hepes + 2.200 g NaHC03 / I + lO,uM histamine) to which the NHE inhibitor cariporide was added in a concentration of lO,uM.
Change to the same medium without corresponding addition of inhibitor served as control.
The samples taken from the supernatant were used to determine the vWF
concentration. This was done by an ELISA method (enzyme-linked immuno sorbent assay) using specific antibodies. The vWF content of standard human plasma (Behring, Marburg) is calculated using an international standard (2'~
International Standard 87/718; National Institute for Biological Standards and Control, London).
Table 3: vWF conzentration in the cell supernatant under acidotic (vWF~,~,~
and under control conditions (vWF~~, measured after incubation for 15 minutes. The vWF concentration under control conditions is set at 100.
Table 3.
vW F~o 100~~
vWFa~d~,s (constitutive) 46 1.1 VWFa~,ao~s (stimulated, histamine52 2.5~
NM) The acidosis led to a distinct decrease in vWF secretion, both the constitutive secretion and the stimulated Weibei-Palade body secretion. The vWF secretion was reduced by a factor of 2 compared with control cells during acidosis (pHex = 6.4).
Table 4: vWF secretion was measured during a 10-minute repertusion time with stimulation. The vWF secretion of the control cells (vWF~~ was set at 100. The vWF concentration during the repertusion of preacidotic cells (vWF~,~ and the vWF concentration durlrig reperfusion of preacidotic cells in the presence of 1 O,uM of cariporide (vWF,,~) have been indicated as values relative to the control values. Control cells were incubated with cariporide (vWF~o+,~) Table 4:
vWF~o 100 vWF~o+HOe 106 t 3.06 vWFa~,d~,s 193 t 8.0~
vWF,~ 139 16~
During the reperfusion there was a large increase in vWF secretion by a factor of 2. Blockade of the NHE with cariporide reduces the increased vWF secretion by almost 60~ and thus approaches the control values. Control cells incubated with cariporide (10 ~.M) showed no increase or decrease in vWF secretion.
The examples showed that extracellular acidosis as present for example during ischemia led to an intracellular acidosis, resulting in reduced (constitutive and stimulated) vWF secretion and a reduced P-selectin expression. The subsequent reperfusion and stimulation of the endothelial cells brought about rapid intracellular realkalinization. There was a simultaneous great enhancement of the increased vWF secretion and increased P-selectin expression. A delay of the realkalinization with cariporide reduced the increased vWF secretion and P-selectin expression and thus the possible thrombosis and inflammatory reactions. The examples showed that the intracellular pH is determined by the extracellular pH. Secretion by the endothelial cells is in turn determined by the intracellular pH. It is thus possible, by inhibiting realkalinization, to reduce greatly the known endothelial cell activation during the reperfusion phase and the worry, connected therewith, about rethrombosis (vWF secretion) and inflammation. Incubation of healthy, non-acidotic control cells with cariporide showed no effect. This indicates a low potential for side effects and prevents an excessive tendency to bleeding. The agent acts only where ischemia is present.
Claims (4)
1. The use of a) inhibitors of the sodium/hydrogen exchanger selected from the group and/or their stereoisomeric form and/or mixtures of these forms in any ratio, and/or the physiologically tolerated salts of the abovementioned compounds, in combination with b) anticoagulant, platelet aggregation-inhibiting or fibrinolytic agents for producing medicaments for the prophylaxis and therapy of acute or chronic diseases which are caused by elevated levels of von Willebrand factor in the blood and/or increased expression of P-selectin selected from the group of thromboses in acute myocardial, mesenteric or else cerebral infarction; thrombotic disorders occurring during or after surgical operations; pulmonary embolisms; deep vein thromboses as occur at an increased rate after prolonged restriction of blood flow, especially in the lower extremities, for example after prolonged lying or sitting, and imflammatory disorders as occur during ischemia and subsequent reperfusion, during vasculitis such as associated with an autoimmune disease or connective tissue disease, or an incipient inflammatory reaction, prophylaxis and treatment of arteriosclerosis, prophylaxis and treatment of cancer or treatment of inflammations of joints and arthritic disorders such as rheumatoid arthritis.
2. The use as claimed in claim 1, wherein cariporide is employed as inhibitor of the sodium/hydrogen exchanger.
3. The use as claimed in claim 1 or 2, wherein the anticoagulant, platelet aggregation-inhibiting or fibrinolytic agents are selected from the group of factor Xa inhibitors, standard heparin, low molecular weight heparins such as enoxaparin, dalteparin, certroparin, parnaparin or tinzaparin, direct thrombin inhibitors such as hirudin, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator.
4. The use as claimed in one or more of claims 1 to 3, wherein the agents are administered by oral, inhalational, rectal or transdermal administration or by subcutaneous, intraarticular, intraperitoneal or intravenous injection.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10206358A DE10206358A1 (en) | 2002-02-14 | 2002-02-14 | Use of inhibitors of the sodium-hydrogen exchanger for the treatment of thrombotic and inflammatory diseases |
DE10206358.3 | 2002-02-14 | ||
PCT/EP2003/001020 WO2003068212A1 (en) | 2002-02-14 | 2003-02-03 | Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2476446A1 true CA2476446A1 (en) | 2003-08-21 |
Family
ID=27634998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002476446A Abandoned CA2476446A1 (en) | 2002-02-14 | 2003-02-03 | Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1480628A1 (en) |
JP (1) | JP2005525336A (en) |
AR (1) | AR038502A1 (en) |
AU (1) | AU2003208368A1 (en) |
BR (1) | BR0307618A (en) |
CA (1) | CA2476446A1 (en) |
DE (1) | DE10206358A1 (en) |
MX (1) | MXPA04007387A (en) |
TW (1) | TW200403988A (en) |
WO (1) | WO2003068212A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10305070A1 (en) * | 2003-02-07 | 2004-08-26 | Merck Patent Gmbh | Use of sodium-hydrogen ion antiporter 1 inhibitors e.g. N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine, used at doses causing only partial inhibition, e.g. for treating arrhythmia or angina |
HUE026025T2 (en) * | 2008-05-09 | 2016-05-30 | Merck Patent Gmbh | Pharmaceutical composition comprising rimeporide for treating diseases associated with beta-cell dysfunction |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627193A (en) * | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
DE19734693A1 (en) * | 1997-08-11 | 1998-01-22 | Hoechst Marion Roussel De Gmbh | Use of cariporide to treat cardiac and non-cardiac disease |
-
2002
- 2002-02-14 DE DE10206358A patent/DE10206358A1/en not_active Withdrawn
-
2003
- 2003-02-03 CA CA002476446A patent/CA2476446A1/en not_active Abandoned
- 2003-02-03 AU AU2003208368A patent/AU2003208368A1/en not_active Abandoned
- 2003-02-03 JP JP2003567394A patent/JP2005525336A/en not_active Abandoned
- 2003-02-03 BR BR0307618-0A patent/BR0307618A/en not_active IP Right Cessation
- 2003-02-03 WO PCT/EP2003/001020 patent/WO2003068212A1/en not_active Application Discontinuation
- 2003-02-03 MX MXPA04007387A patent/MXPA04007387A/en not_active Application Discontinuation
- 2003-02-03 EP EP03706415A patent/EP1480628A1/en not_active Withdrawn
- 2003-02-12 TW TW092102811A patent/TW200403988A/en unknown
- 2003-02-12 AR ARP030100448A patent/AR038502A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA04007387A (en) | 2004-10-11 |
EP1480628A1 (en) | 2004-12-01 |
TW200403988A (en) | 2004-03-16 |
AR038502A1 (en) | 2005-01-19 |
JP2005525336A (en) | 2005-08-25 |
AU2003208368A1 (en) | 2003-09-04 |
WO2003068212A1 (en) | 2003-08-21 |
DE10206358A1 (en) | 2003-08-28 |
BR0307618A (en) | 2004-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5192772A (en) | Therapeutic agents | |
US7365080B2 (en) | Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof | |
JP4212114B2 (en) | P1, P4-dithio-P2-P3-monochloromethylene 5 ', 5 "'-diadenosine P1, P4-tetraphosphate as antithrombotic agent | |
US20060025401A1 (en) | Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders | |
CN1274281A (en) | Compsns. for treating and preventing arterial thrombosis and use of factor Xa inhibitor on its own and/or combined with platelet antiaggegating agent | |
JP2022513919A (en) | Substituted oxopyridine derivatives for the treatment and / or prevention of thrombotic or platelet embolic disease and / or thrombotic or platelet embolic complications | |
CA2476446A1 (en) | Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases | |
US20040097583A1 (en) | Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders | |
JPH08301754A (en) | Medicine composition for medical treatment of disease related to na ion non-dependent cl ion/carbonic acid hydrogen ion exchanger | |
US6335330B1 (en) | Crystalline pharmaceutical product | |
CN101486715B (en) | Novel oxazine compound and use for preventing platelet aggregation | |
CA2476454A1 (en) | Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases | |
EP0411704A1 (en) | Substituted aromatic sulfonamides as antiglaucoma agents | |
US4014993A (en) | Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds | |
CA2285350A1 (en) | Treatment for pulmonary fibrosis | |
JP2987727B2 (en) | Endogenous calcium release inhibitor containing diphenylborane derivative as active ingredient | |
EP0319986B1 (en) | Anti-plasmin depressant | |
JPH08505867A (en) | Combination of soluble complement receptor 1 (SCR-1) and amidinophenyl or amidinonaphthyl ester for the treatment of inflammation | |
US4321266A (en) | 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine | |
US20090118334A1 (en) | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker | |
KR20000068406A (en) | Crystalline Pharmaceutical Product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |